Crossmark

ASO Visual Abstract: A 3-Year Survival Update From a Phase II Study of Paclitaxel Plus Cisplatin and 5-Fluorouracil Induction Chemotherapy for Locally Advanced Borderline-Resectable Esophageal Squamous Cell Carcinoma: The NEOCRTEC-1601 Clinical Trial

Crossref DOI link: https://doi.org/10.1245/s10434-023-14801-9

Published Online: 2024-01-20

Published Print: 2024-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Jia-Di

Wang, Zhi-Qiang

Li, Qiao-Qiao

Li, Zhi-Chao

Ren, Chao

Wang, De-Shen

Chen, Ji-Yang

Tan, Qiong

Li, Yu-Hong

Yang, Hong
License Information

Text and Data Mining valid from 2024-01-20

Version of Record valid from 2024-01-20
More Information

Article History

First Online: 20 January 2024

DISCLOSURE

: Jia-Di Wu, Zhi-Qiang Wang, Qiao-Qiao Li, Zhi-Chao Li, Chao Ren, De-Shen Wang, Ji-Yang Chen, Qiong Tan, Yu-Hong Li, and Hong Yang declare they have no conflicts of interest in relation to this work.

Document is current

Any future updates will be listed below